Choosing the best PRESCRIPTION preventive migraine treatment for you (if you have episodic migraines)!
Posted on September 18 2022,
The below isn't medical advice, but educational knowledge to go prepared with when meeting with your neurologist.
Episodic migraines are migraines that occur less than 15 times per month. Anything more is chronic migraines.
Let’s get to the point so you don’t need to read more information than you want.
There are 4 main categories you should expect to be prescribed if you have episodic migraines.
Beta blockers: metoprolol, propranolol, timolol
Antidepressants (there are two of different classes): Amitriptyline (a TCA) and venlafaxine (an SNRI)
Anticonvulsants: Valproate (valproic acid), topiramate (more commonly known as the brand name Topamax)
CGRP antagonists: Rimegepant, atogepant, fremanezumab, galcanezumab, eptinezumab.
Due to high cost and hurdles health insurance will put you through, at least in the states, CGRP antagonists are generally only prescribed when other classes have failed. (Yes, I know, this is terrible since they generally work well- at least for a period of time).
Now, which medication is chosen for you as a patient? This requires individualized patient care and a good understanding of a patient’s medical history.
Depression? An antidepressant like the ones listed above may be of benefit.
Insomnia? Amitriptyline.
Obesity? Topamax
Autoimmune condition with Raynaud’s or Raynaud’s alone? Calcium channel blockers. Why aren’t they listed above with the other classes? Data isn’t so great.
Does the patient have hypertension and is less than 60 years of age and a nonsmoker? Then going for the beta blockers is best barring no contraindications. (For smokers or over the age of 60, beta blockers may increase the rate of cardiovascular events so a calcium channel blocker may be indicated instead).
Treatment failure or side effects? Switch to another class.
Wed, Jan 14, 26
New Emergency Department Migraine Treatment Guidelines
The American Headache Society (AHS) has released its 2025 guideline update for the acute treatment of migraine in adults presenting to the emergency department. This update, published in Headache in...
Read MoreSun, Jan 04, 26
Long-Term Safety of Anti-CGRP Monoclonal Antibodies
A comprehensive meta-analysis of over 4,300 patients reveals that erenumab, galcanezumab, fremanezumab, and eptinezumab maintain good tolerability beyond 12 months. Only 3% of patients stopped treatment due to adverse events,...
Read MoreThu, Jan 01, 26
Alternate Nostril Breathing Protocol for Migraine
Alternate nostril breathing is a simple yogic technique that's showing real promise for migraine prevention. Unlike acute treatments, this practice builds nervous system resilience over time - making attacks less...
Read More
